Granted Patent
B2
US 12,668,643 · App. 18/206,645 · Granted Jun 30, 2026
Modular platform for targeted therapeutics
Inventors:
Ranit Kedmi (Tel-Aviv, IL); Nuphar Veiga (Yaukum, IL); Itai Benhar (Rehovot, IL); Dan Peer (Kiryat-Ono, IL)
Assignee:
Ramot at Tel-Aviv University Ltd.
C07K16/30A61K9/127A61K47/543A61P35/00C07K16/2809C07K16/2812C07K16/2815C07K16/2845C07K16/2866C07K16/2896C07K16/4241C12N15/11C12N15/111C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.
Claims (18)
1 . A lipid nanoparticle comprising a lipidated polypeptide non-covalently attached to an outer surface of the lipid nanoparticle, wherein the lipidated polypeptide is a fusion protein comprising, from N-terminus to C-terminus, an inner membrane lipidation signal peptide from an inner membrane bacterial lipoprotein for anchoring the lipidated polypeptide to the lipid nanoparticle non-covalently and an antibody fragment selected from the group consisting of a Fv, a single chain Fv (scFv), a disulfide-stabilized Fv (dsFv), an Fab, an Fab′, and an F(ab′) 2 that selectively binds an antigen.
2 . The lipid nanoparticle of claim 1 , wherein said antibody fragment comprises a scFv, a variable region of a light chain, or an Fd fragment of a heavy chain.
3 . The lipid nanoparticle of claim 1 , wherein said antibody fragment is a humanized or human antibody fragment.
4 . The lipid nanoparticle of claim 1 , wherein said inner membrane lipidation signal peptide comprises SEQ ID NO: 13.
5 . The lipid nanoparticle of claim 1 , wherein said inner membrane lipidation signal peptide consists of SEQ ID NO: 13.
6 . The lipid nanoparticle of claim 1 , wherein said lipid nanoparticle comprises a charged external surface.
7 . The lipid nanoparticle of claim 1 , wherein said lipid nanoparticle comprises cationic lipids.
8 . The lipid nanoparticle of claim 1 , wherein said lipid nanoparticle is loaded with a diagnostic or a therapeutic agent.
9 . The lipid nanoparticle of claim 8 , wherein said therapeutic agent is a nucleic acid agent.
10 . The lipid nanoparticle of claim 9 , wherein said nucleic acid agent is a DNA, RNA, siRNA, plasmid DNA, short-hairpin RNA, small temporal RNA (stRNA), microRNA (miRNA), RNAmimetic or heterochromatic siRNA.
11 . The lipid nanoparticle of claim 10 , wherein said nucleic acid agent is a siRNA.
12 . A method of producing the lipid nanoparticle of claim 1 , the method comprising incubating a lipidated polypeptide that is a fusion protein comprising, from N-terminus to C-terminus, an inner membrane lipidation signal peptide from an inner membrane bacterial lipoprotein and an antibody fragment selected from the group consisting of a Fv, a single chain Fv (scFv), a disulfide-stabilized Fv (dsFv), an Fab, an Fab′, and an F(ab′) 2 that selectively binds an antigen with a lipid nanoparticle, wherein the inner membrane lipidation signal peptide anchors the lipidated polypeptide fusion protein to the lipid nanoparticle.
13 . The method of claim 12 , wherein said method comprises isolating said lipidated polypeptide from a bacteria into detergent micelles prior to said incubating.
14 . A method of delivering a diagnostic or a therapeutic agent to a subject in need thereof, the method comprising administering to the subject the lipid nanoparticle of claim 8 , thereby delivering the diagnostic or the therapeutic agent to the subject.
15 . The lipid nanoparticle of claim 1 , wherein said inner membrane bacterial lipoprotein is selected from the group consisting of AraH, MglC, MalF, MalG, MalC, MalD, RbsC, RbsC, ArtM, ArtQ, GlnP, ProW, HisM, HisQ, LivH, LivM, LivA, LivE, DppB, DppC, OppB, AmiC, AmiD, BtuC, FhuB, FecC, FecD, FecR, FepD, NikB, NikC, CysT, CysW, UgpA, UgpE, PstA, PstC, PotB, PotC, PotiH, Potl, ModB, NosY, PhnM, LacY, SecY, TolC, DsbB, DsbD, TonB, TatC, CheY, TraB, Exb D, ExbB and Aas.
16 . The lipid nanoparticle of claim 1 , wherein said inner membrane bacterial lipoprotein is E. coli new lipoprotein A (NlpA).
17 . The lipid nanoparticle of claim 1 , wherein said inner membrane bacterial lipoprotein is K. pneumoniae pullulanase.
18 . The lipid nanoparticle of claim 1 , wherein said inner membrane lipidation signal peptide comprises SEQ ID NO: 17.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 19, 2023
From: KEDMI, RANIT; VEIGA, NUPHAR; BENHAR, ITAI; PEER, DAN
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 063982/0097 →
Continuity (3)
Continuation
16316629
Provisional Application
62363417
· Jul 18, 2016
References Cited (176)
US 3850578A
· McConnell et al.
· 1974
[cited by applicant]
US 3853987A
· Dreyer et al.
· 1974
[cited by applicant]
US 3867517A
· Ling
· 1975
[cited by applicant]
US 3901654A
· Gross
· 1975
[cited by applicant]
US 3935074A
· Rubenstein et al.
· 1976
[cited by applicant]
US 3984533A
· Uzgiris
· 1976
[cited by applicant]
US 3996345A
· Ullman et al.
· 1976
[cited by applicant]
US 4034074A
· Miles et al.
· 1977
[cited by applicant]
US 4036945A
· Haber
· 1977
[cited by applicant]
US 4098876A
· Piasio et al.
· 1978
[cited by applicant]
US 4331647A
· Goldenberg
· 1982
[cited by applicant]
US 4666828A
· Gusella
· 1987
[cited by applicant]
US 4683202A
· Mullis
· 1987
[cited by applicant]
US 4801531A
· Frossard
· 1989
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4873316A
· Meade et al.
· 1989
[cited by applicant]
US 4879219A
· Wands et al.
· 1989
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5011771A
· Bellet et al.
· 1991
[cited by applicant]
US 5192659A
· Simons
· 1993
[cited by applicant]
US 5272057A
· Smulson et al.
· 1993
[cited by applicant]
US 5281521A
· Trojanowski et al.
· 1994
[cited by applicant]
US 5464764A
· Capecchi et al.
· 1995
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5569825A
· Lonberg et al.
· 1996
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Lonberg et al.
· 1997
[cited by applicant]
US 5661016A
· Lonberg et al.
· 1997
[cited by applicant]
US 5814318A
· Lonberg et al.
· 1998
[cited by applicant]
US 6440736B1
· Logtenberg et al.
· 2002
[cited by applicant]
US 7094571B2
· Harvey et al.
· 2006
[cited by applicant]
US 7575871B2
· Griffin et al.
· 2009
[cited by applicant]
US 7611866B2
· Georgiou et al.
· 2009
[cited by applicant]
US 8067179B2
· Georgiou et al.
· 2011
[cited by applicant]
US 8535890B2
· Kashmiri et al.
· 2013
[cited by applicant]
US 20060029947A1
· Georgiou
· 2006
[cited by examiner]
US 20070099267A1
· Harvey et al.
· 2007
[cited by applicant]
US 20110206740A1
· Karp
· 2011
[cited by examiner]
US 20130064762A1
· Simon
· 2013
[cited by applicant]
US 20240246898A1
· Peer et al.
· 2024
[cited by applicant]
US 20250057924A1
· Sobol
· 2025
[cited by applicant]
US 20250162978A1
· Peer et al.
· 2025
[cited by applicant]
EP 0506124
· 1992
[cited by applicant]
WO WO9107987
· 1991
[cited by applicant]
WO WO9901556
· 1999
[cited by applicant]
WO WO2005060457
· 2005
[cited by applicant]
WO WO2006078987
· 2006
[cited by applicant]
WO WO2006082406
· 2006
[cited by applicant]
WO WO2007127272
· 2007
[cited by applicant]
WO WO2008116149
· 2008
[cited by applicant]
WO WO2011139792
· 2011
[cited by applicant]
WO WO2014041544
· 2014
[cited by applicant]
WO WO2014204726A1
· 2014
[cited by applicant]
WO WO2016189532A1
· 2016
[cited by applicant]
WO WO2017173054A1
· 2017
[cited by applicant]
WO WO2018015881
· 2018
[cited by applicant]
WO WO2018087753A1
· 2018
[cited by applicant]
WO WO2021234694A1
· 2021
[cited by applicant]
WO WO2022168085A1
· 2022
[cited by applicant]
WO WO2023122036A1
· 2023
[cited by applicant]
WO WO2023122038A1
· 2023
[cited by applicant]
WO WO2024100656A1
· 2024
[cited by applicant]
WO WO2024257088A1
· 2024
[cited by applicant]
De Kruif et al., FEBS Letter 399: 232-236 (Year: 1996).
[cited by examiner]
Lloyd et al., Protein Engineering, Design & Selection 22:159-168 (Year: 2009).
[cited by examiner]
Edwards et al., J Mol Biol. 334(1): 103-118 (Year: 2003).
[cited by examiner]
Poosarla et al., Biotechn. Bioeng. 114(6): 1831-1342 (Year: 2017).
[cited by examiner]
Chiu et al., Antibodies 8: 1-80 (Year: 2019).
[cited by examiner]
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 79(6):1979-1983 (Year: 1982).
[cited by examiner]
Colman P. M., Research in Immunology, 145:33-36 (Year: 1994).
[cited by examiner]
Advisory Action Dated Nov. 9, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (3 Pages).
[cited by applicant]
Applicant-Initiated Interview Summary Dated Apr. 12, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (3 pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Sep. 4, 2018 From the European Patent Office Re. Application No. 13779639.7. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Apr. 7, 2022 From the European Patent Office Re. Application No. 17830577.7. (5 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated May 29, 2019 From the European Patent Office Re. Application No. 13779639.7. (4 Pages).
[cited by applicant]
Final Official Action Dated Jul. 2, 2021 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (9 pages).
[cited by applicant]
Final Official Action Dated May 24, 2022 from US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (11 pages).
[cited by applicant]
Final Official Action Dated Aug. 25, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (16 pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Mar. 26, 2015 From the International Bureau of WIPO Re. Application No. PCT/IL2013/050775.
[cited by applicant]
International Preliminary Report on Patentability Dated Jan. 31, 2019 From the International Bureau of WIPO Re. Application No. PCT/IB2017/054334. (11 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Nov. 8, 2017 From the International Searching Authority Re. Application No. PCT/IB2017/054334. (15 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Feb. 21, 2014 From the International Searching Authority Re. Application No. PCT/IL2013/050775.
[cited by applicant]
Invitation to File a Search Results or a Statement of Non-Availability Pursuant to Rule 70b(1) EPC Dated Dec. 8, 2015 From the European Patent Office Re. Application No. 13779639.7.
[cited by applicant]
Notice of Allowance Dated Mar. 2, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (6 pages).
[cited by applicant]
Notice of Allowance Dated Feb. 17, 2022 from US Patent and Trademark Office Re. U.S. Appl. No. 16/701,184. (21 pages).
[cited by applicant]
Notice Of Allowance Dated Sep. 30, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (6 pages).
[cited by applicant]
Office Action and Search Report Dated Mar. 17, 2013 From the Israel Patent Office Re. Application No. 221909.
[cited by applicant]
Official Action Dated Feb. 8, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (11 pages).
[cited by applicant]
Official Action Dated Mar. 9, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (25 pages).
[cited by applicant]
Official Action Dated Nov. 14, 2022 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (6 pages).
[cited by applicant]
Official Action Dated Mar. 18, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (7 pages).
[cited by applicant]
Official Action Dated Jul. 19, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (10 pages).
[cited by applicant]
Official Action Dated Sep. 20, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (10 pages).
[cited by applicant]
Official Action Dated Mar. 23, 2021 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (9 pages).
[cited by applicant]
Official Action Dated Dec. 24, 2021 from US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (12 pages).
[cited by applicant]
Official Action Dated Dec. 30, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711. (14 pages).
[cited by applicant]
Restriction Official Action Dated Sep. 9, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/427,711.
[cited by applicant]
Restriction Official Action Dated Oct. 30, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,629. (6 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Mar. 12, 2020 From the European Patent Office Re. Application No. 17830577.7. (9 Pages).
[cited by applicant]
Ansell et al. “Antibody Conjugation Methods for Active Targeting of Liposomes”, Methods in Molecular Medicine: Drug Targeting: Strategies, Principles, and Applications, 25(Chap.4): 51-67, 2000.
[cited by applicant]
Begent et al. “Liposomally Entrapped Second Antibody Improves Tumour Imaging With Radiolabelled (First) Antitumour Antibody”, The Lancet, XP055101004, p. 739-742, Oct. 2, 1982. Abstract, p. 739, 741, r-h Col.
[cited by applicant]
Ben-Arie et al. “Integrin-Targeted Nanoparticles for siRNA Delivery”, Integrin and Cell Adhesion Molecules: Methods and Protocols, Methods in Molecular Biology, XP055136709, 757(Chap.29): 497-507, Published Online Jun. …
[cited by applicant]
Braisted et al. “Minimizing A Binding Domain From Protein A”, Proc. Natl. Acad. Sci. USA, 93(12): 5688-5692, Jun. 11, 1996.
[cited by applicant]
Choe et al. “Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides”, Materials, 9(12): 994-1-994-17, Dec. 8, 2016.
[cited by applicant]
De Kruif et al. “Biosynthetically Lipid-Modified Human ScFv Fragments From Phage Display Libraries as Targeting Molecules for Immunoliposomes”, FEBS Letters, 399(3): 232-236, Dec. 16, 1996.
[cited by applicant]
Delgoffe et al. “Enhanced Interaction Between Hsp90 and Raptor Regulates mTOR Signaling Upon T Cell Activation”, Molecular immunology, 46(13): 2694-2698, Aug. 1, 2009.
[cited by applicant]
Harvey et al. “Anchored Periplasmic Expression, A Versatile Technology for the Isolation of High-Affinity Antibodies From
[cited by applicant]
Jeong et al. “Efficiant Selection of IgG Fc Domain-Binding Peptides Fused to Fluorescent Protein Using
[cited by applicant]
Jones et al. “Blood-Brain Barrier Transport of Therapeutics Via Receptor-Mediation”, Pharmaceutical Research, XP019532601, 24(9): 1759-1771, Jul. 10, 2007. Abstract, p. 1767-1769.
[cited by applicant]
Julien et al. “Utilization of Monoclonal Antibody-Targeted Nanomaterials in the Treatment of Cancer”, MAbs, 3(5): 467-478, Sep./Oct. 2011.
[cited by applicant]
Kedmi et al. “A Modular Platform for Targeted RNAi Therapeutics”, Nature Nanotechnology, XP036449126, 13(3): 214-219, Published Online Jan. 29, 2018.
[cited by applicant]
Kruif et al. “Biosynthetically Lipid-Modified Human scFv Fragments From Phage Display Libraries as Targeting Molecules for Immunoliposomes”, FEBS Letters, 399(3): 232-236, Dec. 16, 1996.
[cited by applicant]
Krystofiak et al. “Elimination of Tumor Cells Using Folate Receptor Targeing by Antibody-Conjugated, Gold-Coated Magnetite Nanoparticles in a Murine Breast Cancer Model”, Journal of Nanomaterials, 2012: Article ID 43101…
[cited by applicant]
Laukkanen et al. “Lipid-Tagged Antibodies: Bacterial Expression and Characterization of a Lipoprotein—Single-Chain Antibody Fusion Protein”, Protein Engineering, 6(4): 449-454, 1993.
[cited by applicant]
Leserman et al. “Targeting to Cells of Fluorescent Liposomes Covalently Coupled With Monoclonal Antibody or Protein A”, Nature, 288: 602-604, Dec. 11, 1980.
[cited by applicant]
Li et al. “Electrochemical Immunosensors for Cancer Biomarker With Signal Amplification Based on Ferrocene Functionalized Iron Oxide Nanoparticles”, Biosensors and Bioelectronics, XP028369905, 26(8): 3590-3595, Feb. 4, …
[cited by applicant]
Matthay et al. “Antibody-Directed Liposomes: Comparison of Various Ligands for Association, Endocytosis, and Drug Delivery”, Cancer Research, 46: 4904-4910, Oct. 1986.
[cited by applicant]
Owens “Faster, Deeper, Smaller—The Rise of Antibody-Like Scaffolds”, Nature Biotechnology, 35(7): 602-603, Jul. 2017.
[cited by applicant]
Pitsillides et al. “Selctive Cell Targeting With Light-Absorbing Microparticles and Nanoparticles”, Biophysical Journal, XP002428862, 84(6): 4023-4032, Jun. 1, 2003. p. 4028.
[cited by applicant]
Presta et al. “Humanization of An Antibody Directed Against IgE”, The Journal of Immunology, XP002094432, 151(5): 2623-2632, Sep. 1, 1993. Abstract, p. 2624, 2629-2631.
[cited by applicant]
Ritter et al. “Serological Analysis of Human Anti-Hun: 1 an Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized 1Vlonodonal Antibody A33”, Cancer Research 61:6851-6859, Sep. 15, 2001.
[cited by applicant]
Serda et al. “Quantitative Mechanics of Endothelial Phagocytosis of Silicon Microparticles”, Cytometry Part A, XP008111439, 75(9): 752-760, Sep. 1, 2009. p. 757, r-h Col.
[cited by applicant]
Torchilin “Fluorescence Microscopy to Follow the Targetin of Liposomes and Micelles to Cells and Their Intracellular Fate”, Advanced Drug Delivery Reviews, XP027771274, 57(1): 95-109, Jan. 2, 2005. Abstract, p. 96, Line…
[cited by applicant]
Torchilin et al. “P-Nitrophenylcarbonyl-PEG-PE-Liposomes: Fast and Simple Attachment of Specific Ligands, Including Monoclonal Antibodies, to Distal Ends of PEG Chains Via P-Nitrophenylcarbonyl Groups”, Biochimica et Bi…
[cited by applicant]
Ugelstad et al. “Biomedical Applications of Monodisperse Magnetic Polymer Particles”, Nato Advanced Science Institute, XP000603237, p. 355-370, Jan. 1, 1987. p. 361.
[cited by applicant]
Van der Heyde et al. “Analysis of Antigen-Specific Antibodies and Their Isotypes in Experimental Malaria”, Cytometry Part A, The Journal of the International Society for Analytical Cytology, 71(4): 242-250, 2007.
[cited by applicant]
Vazquez-Lombardi et al. “Challenges and Opportunities for Non-Antibody Scaffold Drugs”, Drug Discovery Today, 20(10): 1271-1283, Oct. 2015.
[cited by applicant]
Wu et al. “Immunofluorescence Labeling of Cancer Marker Her2 and Other Cellular Targets With Semiconductor Quantum Dots”, Nature Biotechnology, 21: 41-46, Jan. 2003.
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jan. 27, 2025 From the European Patent Office Re. Application No. 24193705.1. (7 Pages).
[cited by applicant]
Banerji, Julian et al. A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell 33(3):729-740 (1983).
[cited by applicant]
Bird, Robert E. et al. Single-chain Antigen-binding Proteins. Science 242(4877):423-426 (1988).
[cited by applicant]
Burkovitz, Anat et al. Computational identification of antigen-binding antibody fragments. The Journal of Immunology. 190(5): 2327-2334 (2013).
[cited by applicant]
Cohen, Zvi R. et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 9(2):1581-1591 (2015).
[cited by applicant]
Collantes, Juan Carlos et al. Development and characterization of a modular CRISPR and RNA aptamer mediated base editing system. The CRISPR Journal 4(1):58-68 (2021).
[cited by applicant]
Dammes, Niels et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nature nanotechnology 16(9):1030-1038 (2021).
[cited by applicant]
Fields, Conor et al. Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. Nature Protocols. 8(6):1125-1148 (2013).
[cited by applicant]
Gibson, Daniel G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature Methods 6(5):343-345 (2009).
[cited by applicant]
Inbar, Dan et al. Localization of antibody-combining sites within the variable portions of heavy and light chains. Proceedings of the National Academy of Sciences 69(9):2659-2662 (1972).
[cited by applicant]
Jeong, Y. K. et al. Current status and challenges of DNA base editing tools. Molecular Therapy 28(9):1938-1952 (2020).
[cited by applicant]
Jeong, Yu-jin et al. Efficient selection of IgG Fc domain-binding peptides fused to fluorescent protein using
[cited by applicant]
Juncker, Agnieszka S. et al. Prediction of lipoprotein signal peptides in gram-negative bacteria. Protein Science 12:1652-1662 (2003).
[cited by applicant]
Leung, Alex K. K. et al. Microfuidic Mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. The Journal of Physical Chemistry B. 119(28): 8698-8706 (2015).
[cited by applicant]
Marks, James D. et al. By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage. Journal of Molecular Biology 222(3):581-597 (1991).
[cited by applicant]
Morrison, S. Immunology. Success in specification. Nature 368(6474):812-813 (1994).
[cited by applicant]
Okuda, Suguru et al. Lipoprotein Sorting in Bacteria. Annu. Rev. Microbiol. 65:239-259 (2011).
[cited by applicant]
Pack, Peter et al. Improved Bivalent Miniantibodies, With Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of
[cited by applicant]
PCT/IL2023/051145 International Search Report and Written Opinion dated Feb. 19, 2024.
[cited by applicant]
Raguram, Aditya et al. Therapeutic in Vivo Delivery of Gene Editing Agents. Cell 185(15):2806-2827 (2022).
[cited by applicant]
Ramishetti, Srinivas et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Advanced materials 32(12):e1906128, 1-8 (2020).
[cited by applicant]
Riechmann, Lutz et al. Reshaping Human Antibodies for Therapy. Nature 332(6162):323-327 (1988).
[cited by applicant]
Rosenblum, Daniel et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances 6(47):eabc9450, 1-12 (2020).
[cited by applicant]
Tarab-Ravski, Dana et al. Delivery of therapeutic RNA to the bone marrow in multiple myeloma using CD38-targeted lipid nanoparticles. Advanced Science 10(21):2301377, 1-13 (2023).
[cited by applicant]
Tokuda, Hajime et al. Sorting of lipoproteins to the outer membrane in
[cited by applicant]
Veiga, Nuphar et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nature communications 9(1):4493, 1-9 (2018).
[cited by applicant]
Veiga, Nuphar et al. Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. Journal of Controlled Release 313:33-41 (2019).
[cited by applicant]
Weinstein, Shiri et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proceedings of the National Academy of Sciences 113(1):E16-E22 (2016).
[cited by applicant]
Whitlow, Marc, and David Filpula. Single-Chain Fv Proteins and Their Fusion Proteins. Methods: A Companion to Methods in Enzymology 2(2):97-105 (1991).
[cited by applicant]
Yang, Y et al. Construction and adhesive properties of a soluble MAdCAM-1-Fc chimera expressed in a baculovirus system: Phylogenetic conservation of receptor-ligand interaction. Scandinavian journal of immunology 42(2):…
[cited by applicant]
Yu, Yamei et al. Structural specializations of α4β7, an integrin that mediates rolling adhesion. Journal of Cell Biology 196(1):131-146 (2012).
[cited by applicant]
Zhang, Zhenwu et al. Progress and prospects of gene editing in pluripotent stem cells. Biomedicines 11(8):2168, 1-24 (2023).
[cited by applicant]
Zuckert, Wolfram R. Secretion of bacterial lipoproteins: through the cytoplasmic membrane, the periplasm and beyond. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research 1843(8):1509-1516 (2014).
[cited by applicant]
EP24193705.1 Office Action dated Apr. 13, 2026.
[cited by applicant]
Kobatake, Eiry et al. Targeted delivery using immunoliposomes with a lipid-modified antibody-binding protein. Appl Biochem Biotechnol 163(2):296-303 (2011).
[cited by applicant]